Myasthenia gravis treatment with monoclonal antibody

Monoclonal antibodies are most commonly used as a part of targeted and immune therapy for patients with cancer. But since they significantly impact the immune system's work, some might also help manage various autoimmune diseases, like myasthenia gravis. Moreover, many neurologists implemented monoclonal antibodies in their routine practices. Currently, doctors use a wide variety of different monoclonal antibodies in myasthenia gravis management. A medication called eculizumab has been found to effectively control and reduce Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores. These scores reflect the daily incidents related to the disease and how it affects everyday activities. Other monoclonal antibodies, e. g. , eculizumab, proved to show a significant impact on the overall number of adverse effects (AE) related to myasthenia gravis. Neurologists might consider a single monoclonal antibody of their combination as a treatment method. Furthermore, every myasthenia patient needs to undergo symptomatic therapy to reduce the intensity and likelihood of the most critical symptoms that may pose a threat to their life.